Matches in SemOpenAlex for { <https://semopenalex.org/work/W1510868644> ?p ?o ?g. }
- W1510868644 abstract "The autoimmune disease myasthenia gravis (MG) is characterized by muscle weakness due to a loss of acetylcholine receptors (AChR) at the neuromuscular end plate. Most MG patients have pathogenic antibodies directed against the receptor. We provide further evidence that T cells are important for establishment and continuation of the disease. We have detected pathogenic antibodies capable of transferring disease to mice in healthy twin sisters as well as in their MG affected sisters in two monozygotic twin pairs discordant for MG. However, the healthy twin sisters did not demonstrate T cell responses against the AChR. A further support to the importance of T cells in maintaining the disease is shown in a successful treatment of an MG patient with antibodies targeting CD25. This molecule is expressed on activated cells. The levels of activated T cells, serum levels of IL-10 as well as the soluble costimulatory molecules sCD28, sCD80, sCD86 and sCD152 decreased, suggesting a normalization of an abnormally activated immune system. Costimulatory molecules are important in the activation and inhibition of an immune response. We demonstrated reduced expression of the costimulatory molecule CD152 (cytotoxic T lymphocyte associated antigen 4, CTLA-4) in T cells from MG patients. CD152 is essential to inhibit an immune response, therefore the patients might have a reduced potential to down-regulate an ongoing immune reaction. We observed that the G allele at position +49 in coding sequence 1 of the CD152 gene was associated to increased immune activity, manifested as increased levels of IL-1β and CD3CD28 cells. MG patients with thymoma more frequently had the G/G genotype or the G allele, which could explain a more active immune response in patients with this genotype. The costimulatory factors CD28, CD80, CD86 and CD152 also exist in soluble forms. The concentrations of sCD28, sCD80, sCD86 and sCD152, all of which recently have been shown to be increased in different diseases, were not increased in MG patients. However, in one of our studies we detected elevated levels of sCD152 in MG patients. The concentrations of sCD28, sCD80, sCD86 and sCD152 correlated to each other and to IL-6, IL-10 and IFN-γ. All four soluble costimulatory molecules correlated to sCD25 in healthy persons, while only sCD80 and sCD86 correlated to sCD25 in MG patients. In addition, we confirmed results by others demonstrating increased serum levels of sCD25 and sICAM-1. We produced a recombinant form of the naturally occurring soluble costimulatory factor CD80. Recombinant sCD80 demonstrated capacity to interact with its natural ligands CD28 and CD152. It preferentially bound to activated cells. In addition, it displayed immunosuppressive properties, demonstrated by inhibition of T cell activation, inhibition of the mixed lymphocyte reaction and the ability to alter the cytokine secretion balance in vitro. The effect of sCD80 in vivo has to be clarified, but it is tempting to speculate about a potential future use of the soluble protein in treatment of diseases like MG. In summary, we have provided further evidence that T cells are important in the initiation and maintenance of MG, and that the costimulatory factors could be involved in disease progression. LIST OF PUBLICATIONS The thesis is based on the following original articles, which are referred to in the text by their Roman numerals: I. Kakoulidou M, Ahlberg R, Yi Q, Giscombe R, Pirskanen R, and Lefvert AK. The autoimmune T and B cell repertoires in monozygotic twins discordant for myasthenia gravis. J Neuroimmunol. 2004, 148 (1-2), pp 183-191 II. Wang XB, Kakoulidou M, Qiu Q, Giscombe R, Huang DR, Pirskanen R, and Lefvert AK. CDS1 and promoter single nucleotide polymorphisms of the CTLA-4 gene in human myasthenia gravis. Genes Immun. 2002, 3, pp 46-49 III. Wang XB, Kakoulidou M, Giscombe R, Qiu Q, Huang DR, Pirskanen R, and Lefvert AK. Abnormal expression of CTLA-4 by T cells from patients with myasthenia gravis: effect of an AT-rich gene sequence. J Neuroimmunol. 2002, 130 (1-2), pp 224-232 IV. Kakoulidou M, Wang XB, Zhao X, Pirskanen R, and Lefvert AK. Soluble costimulatory factors in relation to other markers of immune activation in patients with myasthenia gravis. Manuscript V. Kakoulidou M, Giscombe R, Zhao X, Lefvert AK, and Wang XB. Human soluble CD80 is generated by alternative splicing. Recombinant soluble CD80 binds to CD28 and CD152 and inhibits T cell activation. Submitted VI. Kakoulidou M, Pirskanen R, and Lefvert AK. Treatment of a patient with myasthenia gravis using antibodies against CD25. Manuscript" @default.
- W1510868644 created "2016-06-24" @default.
- W1510868644 creator A5043998424 @default.
- W1510868644 date "2005-09-09" @default.
- W1510868644 modified "2023-09-23" @default.
- W1510868644 title "T cells and costimulatory factors in myasthenia gravis" @default.
- W1510868644 cites W117736859 @default.
- W1510868644 cites W127888354 @default.
- W1510868644 cites W1482285465 @default.
- W1510868644 cites W1511241980 @default.
- W1510868644 cites W1519521580 @default.
- W1510868644 cites W1525601546 @default.
- W1510868644 cites W1531397430 @default.
- W1510868644 cites W1533335323 @default.
- W1510868644 cites W1534774246 @default.
- W1510868644 cites W1542616270 @default.
- W1510868644 cites W1547056855 @default.
- W1510868644 cites W1561559732 @default.
- W1510868644 cites W1566766802 @default.
- W1510868644 cites W1567420244 @default.
- W1510868644 cites W1567647760 @default.
- W1510868644 cites W1568142966 @default.
- W1510868644 cites W1577551786 @default.
- W1510868644 cites W1589505162 @default.
- W1510868644 cites W1592781353 @default.
- W1510868644 cites W1601076556 @default.
- W1510868644 cites W1605218331 @default.
- W1510868644 cites W1620778402 @default.
- W1510868644 cites W1652473508 @default.
- W1510868644 cites W1802024465 @default.
- W1510868644 cites W1839387778 @default.
- W1510868644 cites W1881116487 @default.
- W1510868644 cites W1897024726 @default.
- W1510868644 cites W1899631959 @default.
- W1510868644 cites W1920071306 @default.
- W1510868644 cites W1932802566 @default.
- W1510868644 cites W1963714758 @default.
- W1510868644 cites W1964641337 @default.
- W1510868644 cites W1965134089 @default.
- W1510868644 cites W1965772209 @default.
- W1510868644 cites W1965890581 @default.
- W1510868644 cites W1966102772 @default.
- W1510868644 cites W1966336967 @default.
- W1510868644 cites W1966470919 @default.
- W1510868644 cites W1966847012 @default.
- W1510868644 cites W1967738350 @default.
- W1510868644 cites W1968433393 @default.
- W1510868644 cites W1969770223 @default.
- W1510868644 cites W1971596565 @default.
- W1510868644 cites W1972087622 @default.
- W1510868644 cites W1972745538 @default.
- W1510868644 cites W1974366422 @default.
- W1510868644 cites W1975774951 @default.
- W1510868644 cites W1976021854 @default.
- W1510868644 cites W1976206128 @default.
- W1510868644 cites W1976945431 @default.
- W1510868644 cites W1977298951 @default.
- W1510868644 cites W1977387360 @default.
- W1510868644 cites W1978011938 @default.
- W1510868644 cites W1979009029 @default.
- W1510868644 cites W1979446198 @default.
- W1510868644 cites W1980195256 @default.
- W1510868644 cites W1981561957 @default.
- W1510868644 cites W1982051091 @default.
- W1510868644 cites W1983284248 @default.
- W1510868644 cites W1983468718 @default.
- W1510868644 cites W1984000154 @default.
- W1510868644 cites W1984843671 @default.
- W1510868644 cites W1985643949 @default.
- W1510868644 cites W1986819553 @default.
- W1510868644 cites W1989544242 @default.
- W1510868644 cites W1991164000 @default.
- W1510868644 cites W1991241456 @default.
- W1510868644 cites W1991531286 @default.
- W1510868644 cites W1993094191 @default.
- W1510868644 cites W1993210315 @default.
- W1510868644 cites W1993219448 @default.
- W1510868644 cites W1994015015 @default.
- W1510868644 cites W1995886489 @default.
- W1510868644 cites W1996481500 @default.
- W1510868644 cites W1996875857 @default.
- W1510868644 cites W1997417551 @default.
- W1510868644 cites W1999552103 @default.
- W1510868644 cites W2003336426 @default.
- W1510868644 cites W2003497605 @default.
- W1510868644 cites W2003584062 @default.
- W1510868644 cites W2004470862 @default.
- W1510868644 cites W2007474315 @default.
- W1510868644 cites W2009143590 @default.
- W1510868644 cites W2011030941 @default.
- W1510868644 cites W2011158572 @default.
- W1510868644 cites W2012107785 @default.
- W1510868644 cites W2013010369 @default.
- W1510868644 cites W2013292781 @default.
- W1510868644 cites W2014081699 @default.
- W1510868644 cites W2014364609 @default.
- W1510868644 cites W2014691590 @default.
- W1510868644 cites W2015118926 @default.
- W1510868644 cites W2016439162 @default.
- W1510868644 cites W2016782225 @default.